Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. / Olsen, Jens; Jepsen, Martin Rudbeck.
In: International Journal of Technology Assessment in Health Care, Vol. 26, No. 2, 04.2010, p. 183-191.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark
AU - Olsen, Jens
AU - Jepsen, Martin Rudbeck
PY - 2010/4
Y1 - 2010/4
N2 - Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone. Methods: The analysis was performed in two phases. First, an agent-based transmission model was developed that described the HPV transmission without and with HPV vaccination. Second, an analysis of the incremental costs and effects was performed. The results of prevalence estimates of HPV, genital warts, cervical intraepithelial neoplasia (CIN1-3), and cervical cancer in the model simulations before and after introduction of HPV vaccination were extrapolated to the Danish population figures. Incremental costs and effects were then estimated. Future costs and effects were discounted. Results: Cost-effectiveness ratios for annual vaccination of 12-year-old girls, with a vaccination rate of 70 percent without a catch-up program, were estimated at approximately €1,917 per quality-adjusted life-year (QALY, 3 percent discount rate) and €10,846/QALY (5 percent discount rate), given a 62-year time horizon. Conclusions: A vaccination program would incur extra vaccination costs but would save treatment costs and improve both quality of life and survival.
AB - Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone. Methods: The analysis was performed in two phases. First, an agent-based transmission model was developed that described the HPV transmission without and with HPV vaccination. Second, an analysis of the incremental costs and effects was performed. The results of prevalence estimates of HPV, genital warts, cervical intraepithelial neoplasia (CIN1-3), and cervical cancer in the model simulations before and after introduction of HPV vaccination were extrapolated to the Danish population figures. Incremental costs and effects were then estimated. Future costs and effects were discounted. Results: Cost-effectiveness ratios for annual vaccination of 12-year-old girls, with a vaccination rate of 70 percent without a catch-up program, were estimated at approximately €1,917 per quality-adjusted life-year (QALY, 3 percent discount rate) and €10,846/QALY (5 percent discount rate), given a 62-year time horizon. Conclusions: A vaccination program would incur extra vaccination costs but would save treatment costs and improve both quality of life and survival.
KW - Cervical cancer
KW - Cost-effectiveness
KW - Genital warts
KW - HPV transmission
KW - HPV vaccination
UR - http://www.scopus.com/inward/record.url?scp=77953554172&partnerID=8YFLogxK
U2 - 10.1017/S0266462310000085
DO - 10.1017/S0266462310000085
M3 - Journal article
C2 - 20392322
AN - SCOPUS:77953554172
VL - 26
SP - 183
EP - 191
JO - International Journal of Technology Assessment in Health Care
JF - International Journal of Technology Assessment in Health Care
SN - 0266-4623
IS - 2
ER -
ID: 251356134